NCT00658671已完成1 期
An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 67
- 试验地点
- 2
- 主要终点
- Safety and tolerability of ENMD-2076
研究概览
简要总结
A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have histologic proof of advanced cancer that has progressed after treatment and has no standard therapy that is curative or provides clinical benefit.
- •Meet the modified RECIST Criteria or have disease that can be followed for clinical benefit.
- •Are greater than or equal to 18 years of age.
- •AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- •Total bilirubin ≤ ULN
- •Creatinine ≤ 1.5 x ULN
- •Absolute neutrophil count ≥ 1500 cells/mm3
- •Platelets ≥ 100,000/mm3
- •Hemoglobin ≥ 9.0 g/dL
- •Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Agree to use effective contraceptive methods prior to study entry, during study participation, and for at least 30 days after the last administration of study medication.
- •Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, and agree to return for the required assessments.
排除标准
- •Women who are pregnant or nursing.
- •Have received radiotherapy or chemotherapy less than two weeks prior to first dose of study medication and have not recovered from all acute toxicities from prior treatments.
- •Have participated in any clinical trial involving conventional or investigational drugs within 28 days prior to initiation of ENMD-2076 dosing.
- •Have active, acute, or chronic clinically significant infections.
- •Have uncontrolled severe hypertension or congestive heart failure.
- •Have active angina pectoris or recent myocardial infarction (within 6 months).
- •Have chronic atrial fibrillation or QTc of greater than 470 msec.
- •Have had major surgery within 21 days of starting therapy.
- •Have planned surgical treatment of tumor(s)
- •Have additional uncontrolled serious medical or psychiatric illness.
- •Have any medical condition that would impair the administration of oral agents including significant bowel resection, inflammatory bowel disease or uncontrolled nausea or vomiting.
- •Have a 2+ protein by urinalysis or a history of nephrotic syndrome.
- •Known central nervous system metastasis.
- •Have history of deep vein thrombosis or pulmonary embolus, unless they are receiving therapeutic anticoagulation with warfarin or low-molecular-weight heparin.
研究组 & 干预措施
1
Experimental
Dose-escalation
干预措施: ENMD-2076 (Drug)
2
Experimental
Advanced cancer, excluding patients with colorectal or ovarian cancers
干预措施: ENMD-2076 (Drug)
3
Experimental
Recurrent or resistant epithelial ovarian cancer
干预措施: ENMD-2076 (Drug)
4
Experimental
Colorectal cancer patients who have progressed and/or failed on irinotecan- and oxaliplatin-based regimens
干预措施: ENMD-2076 (Drug)
结局指标
主要结局
Safety and tolerability of ENMD-2076
时间窗: Throughout study treatment
次要结局
- Evidence of benefit (tumor response, clinical benefit, or tumor marker improvement, if appropriate)(Throughout study treatment)
- Plasma PK(Throughout study treatment)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic TumorsNonhematologic Neoplasms, AdvancedNCT02699749Millennium Pharmaceuticals, Inc.80
终止
1 期
Phase 1, Dose-Escalation Study of IGN002 in NHL SubjectsNon-Hodgkin LymphomaNCT02519270Spectrum Pharmaceuticals, Inc62
已完成
1 期
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma PatientsPeripheral T-cell LymphomaNCT02809573Chipscreen Biosciences, Ltd.30
已完成
1 期
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU PatientsUrticaria ChronicNCT03632291United BioPharma15
进行中（未招募）
1 期
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsAdvanced Solid Tumors CancerNCT02988960AbbVie163